New drug cocktail aims to outsmart aggressive blood cancer

NCT ID NCT07680933

Recruiting now Disease control Sponsor: The Affiliated Hospital of Xuzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged 18-80 with CD20-positive DLBCL and an IPI score of 2-5. The main goal is to see how many participants remain cancer-free one year after starting treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orelabrutinib combined with standard immunochemotherapy (Pola-R-CHP or R-CHOP) with or without autologous hematopoietic stem cell transplantation
What this could lead to: If successful, this combination could offer a more effective first-line treatment for aggressive DLBCL, potentially improving long-term disease control and reducing relapse risk.
What could go wrong: This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply broadly. Adding orelabrutinib to chemotherapy increases the risk of side effects like infections, bleeding, and organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Locations

The Affiliated Hospital of Xuzhou Medical University
RECRUITING

Xuzhou, Jiangsu, 221000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.